| Notwithstanding the wishful thinking of certain irresponsible and incompetent public figures, the only options to control and deal with the spread of the Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2) are fast, cheap, reliable, and portable means of diagnosing COVID-19 infection (the name of disease caused by SARS-CoV-2); therapeutics to treat the infected; and vaccines to rapidly build up immunization of large parts of the global population. | |
| In a previous Nanowerk Spotlight we covered nanotechnology-based approaches to testing for COVID-19 infections in high-risk individuals. Today we look at the role of nanotechnology in countering the conventional limitations of antiviral and biological therapeutics. Nanocarriers also have potential to design risk-free and effective immunization strategies for SARS-CoV-2 vaccine candidates such as protein constructs and nucleic acids. | |
| A review paper in ACS Nano (“Nanotechnology for COVID-19: Therapeutics and Vaccine Research”) provides systematic information on nanomedicine strategies employed to deliver small molecules, biologicals (specifically RNAi) and various combination therapies. Some strategies are also proposed for the rational development of this nanomedicine approach and its clinical translation. Since most of the COVID-19 vaccine candidates are sophisticated biological moieties (DNA, mRNA, recombinant proteins, engineered APCs etc.), the scope of nanocarrier delivery becomes highly pertinent. | |
| The authors first describe in great detail the current state of knowledge about the virus’s life cycle, pathophysiology and structure, and then address the organ systems primarily affected by SARS-CoV-2 (it affects the respiratory system first and then spreads systemically to the heart, liver and kidney). | |
Developing SARS-CoV-2 therapeutics |
|
| Today there is no exclusive antiviral treatment against SARS-CoV-2 although therapeutic and prophylactic strategies to deal with existing and potentially upcoming coronavirus infections are under development in research laboratories worldwide. | |
| Using recently available genetic information and protein structure modelling, several therapeutic strategies based on drug repurposing are projected for the immediate treatment of infected patients. | |
| According to the authors, target identification to halt the pathogenesis of the viral infection holds the key in this development: “Viral protease (3CLpro and PLpro), host cell produced protease (TMPRSS2), RNA polymerase (RdRp), interaction site of viral S protein with host receptor ACE2 are among the major targets identified for repurposing already existing antiviral molecules and new small molecules under development.” | |
| Other proposed strategies are targeting the SARS-CoV-2 surface S protein using neutralizing antibody (nAbs) and targeting the SARS-CoV-2 viral RNA genome using RNA interference (RNAi) or antisense oligonucleotides. | |
Developing a vaccine against COVID-19 |
|
| Massive efforts are being employed across the world to develop safe and effective vaccines and several vaccine candidates (see Table 1 in the review for details) have already made it to human clinical trials as a result of fast-tracked development strategies and advanced vaccine technological platforms (read more here in The New England Journal of Medicine: “Developing Covid-19 Vaccines at Pandemic Speed”). | |
| Similar to what researchers are doing in developing SARS-CoV-2 therapeutics, the target strategy for most of the vaccine candidates is to induce nAbs against the viral S protein, averting the ACE2 mediated host uptake. | |
| In the case of SARS-CoV vaccine development, higher nAbs titers and better protection was reported with S protein subunit vaccines when compared to any other target strategy. SARS/MERS vaccine development research suggests S protein subunits, RBD of the S1 subunit and S protein/gene as the most preferred target sites. | |
| The development of COVID-19 vaccine candidates are relying on several high-tech platforms including attenuated and inactivated viruses, replicating and non replicating viral vectors, DNA and mRNA, virus-like particles and recombinant protein-based approaches. |
Image Credit: Envato/ Amanda Scott
News This Week
First complete coronavirus model shows how the spike proteins move cooperatively
The COVID-19 virus holds some mysteries. Scientists remain in the dark on aspects of how it fuses and enters the host cell; how it assembles itself; and how it buds off the host cell. [...]
Researchers discover potential new therapeutic targets on SARS-CoV-2 Spike protein
The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines and therapeutics. Now, a [...]
Tricking the novel coronavirus with a fake ‘handshake’
Scientists have developed protein fragments—called peptides—that fit snugly into a groove on the SARS-CoV-2 Spike protein that it would normally use to access a host cell. These peptides effectively trick the virus into "shaking hands" with a replica rather than with [...]
Researchers reveal genetic predisposition to severe COVID-19
HSE University researchers have become the first in the world to discover genetic predisposition to severe COVID-19. The results of the study were published in the journal Frontiers in Immunology. T-cell immunity is one of [...]
What Pseudoviruses Bring to the Study of SARS-CoV-2
When SARS-CoV-2 first began spreading across the globe, not every lab was equipped to study it directly. The virus behind the current pandemic is highly pathogenic and transmissible, leading the US Centers for Disease [...]
Covid-19: Future targets for treatments rapidly identified with new computer simulations
esearchers have detailed a mechanism in the distinctive corona of Covid-19 that could help scientists to rapidly find new treatments for the virus, and quickly test whether existing treatments are likely to work with [...]
Almost Half of Coronavirus Sufferers Report Depression
Almost half of people testing positive for coronavirus have reported symptoms of depression, according to a new study published in the International Journal of Environmental Research and Public Health. Researchers from Bangladesh, the United States [...]
Six previously FDA-approved drugs appear promising against SARS-CoV-2 in laboratory testing
A team of investigators from the Republic of China has discovered that 6 drugs previously approved by the US Food and Drug Administration (FDA) for other indications could be repurposed to treat or prevent [...]
Graphene could one day be used to make quick, reliable tests for viruses like SARS-CoV-2
Graphene is a layer of carbon only one atom thick. Since it was first isolated in 2004, it has found applications in strengthening materials, accelerating electronics, and boosting performance in batteries, among others. It [...]
UK spots 33 cases of ANOTHER Covid variant
Another Covid variant that could dodge vaccine-triggered immunity has been identified in the UK, scientists say. The strain — called B.1.525 — has been spotted 33 times already but experts say this could be [...]
Spotlight on mRNA vaccines: Covid-19 approvals highlight a novel competitive landscape in oncology
The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications. This historical landmark could have [...]
New AI Tool Can Thwart Coronavirus Mutations
USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial [...]
Pfizer vaccine: Single dose ‘90 per cent effective after 21 days’
A single dose of the Pfizer coronavirus vaccine is “highly protective” after three weeks, according to a study. Researchers at the University of East Anglia (UEA) said the coronavirus vaccine developed by Pfizer and BioNTech was still effective [...]
COVID-19 Attack On Brain, Not Lungs, Triggers Severe Disease In Mice
Summary: Mice exposed to COVID-19 through the nasal passage, researchers noted a rapid and escalated attack on the brain by the virus that triggered a more severe outcome of the infection, even after the lungs [...]
GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine
GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic. The two companies said they plan to work jointly to [...]
Monoclonal antibodies: ‘great hope’ in Covid treatments fails against variants
The great hope for drug treatments against Covid-19 – the monoclonal antibodies – are failing against variants of the virus, such as those that have emerged in South Africa and Brazil, scientists have found. [...]
